<DOC>
	<DOCNO>NCT00230568</DOCNO>
	<brief_summary>12-week , open-label study evaluate effectiveness safety donepezil hydrochloride Hispanic patient mild moderate Alzheimer 's Disease ( AD ) U.S .</brief_summary>
	<brief_title>EARTH 413 : A Study Aricept Hispanic Patients With Mild Moderate Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients selfidentify Hispanic currently live United States . Age range : Patients &gt; = 50 year . Sex distribution : men woman . Women must two ( 2 ) year postmenopausal surgically sterile . MMSE score 10 26 ( inclusive ) . Patients must diagnostic evidence AD ( DSMIV NINCDS/ADRDA criterion ) either prior screening visit . Patients AD may also cerebrovascular disease evidence risk factor hypertension , diabetes , elevate cholesterol level , smoking also eligible enroll study . In order enrol , patient ' clinical condition must control , must investigator 's opinion patient 's primary diagnosis AD , vascular dementia . The diagnosis AD must record patient 's clinical record prior baseline visit . CT MRI within last 12 month consistent diagnosis AD without clinically significant comorbid pathology find . Patients vascular change may include provided meet NINDSAIREN criterion probable Vascular Dementia ( VaD ) . A copy report require appended case report form . If significant change clinical status suggestive stroke neurological disease addition AD onset time last CT MRI screen evaluation , scan repeat screen . All patient must naïve Aricept® treatment . Previous use approve unapproved cholinesterase inhibitor ( Exelon® , Cognex® , Reminyl®/Razadyne® , metrifonate , physostigmine ) memantine allow provided medication discontinue least 3 month prior screen discontinuation do purpose enrol patient trial . Patients must reside community . ( Residence assist live facility allow . ) Patients must reliable caregiver family member agree accompany patient clinic visit , provide information patient require protocol , ensure compliance medication schedule . The caregiver must minimum three day per week direct contact patient ( least 4 hour per day waking hour ) . The patient must capable reliably complete study assessment include efficacy parameter ( MMSE , SDMT , FOME ) procedure schedule screening , baseline followup visit . Patients must clinical laboratory value within normal limit , within Eisai ( sponsor ) guideline , abnormality consider clinically significant investigator sponsor . Patients stable insulindependent diabetes diabetes stabilized diet and/or oral hypoglycemic agent eligible provide monitor regularly ensure adequacy control . Patients know diabetes HbA1c &lt; 8 % screening . Patients controlled hypertension ( sit diastolic BP &lt; 95 mmHg ) , right bundle branch block ( complete partial ) , pacemaker may include study . Patients thyroid disease also may include study provide euthyroid stable treatment least 3 month prior screen , stable treatment maintain throughout study . Patients history seizure disorder allow provide stable treatment least 3 month seizure within past 6 month . Patients must able swallow tablet medication crush tablet allow . Patient must ambulatory ambulatoryaided ( i.e. , walker cane , wheelchair ) . His/her vision hearing ( eyeglasses and/or hearing aid permissible ) must sufficient compliance test procedure . EXCLUSION CRITERIA : Age range : Patients &lt; 50 year . MMSE score &lt; 10 &gt; 26 . Patients active clinically significant condition affect absorption , distribution metabolism study medication ( e.g. , inflammatory bowel disease , gastric duodenal ulcer severe lactose intolerance ) . Patients know hypersensitivity piperidine derivative cholinesterase inhibitor . Patients without reliable caregiver , patient caregiver unwilling unable complete outcome measure fulfill requirement study . Patients live skilled nursing facility ( nursing home ) expect enter nursing home within next 3 month . Patients clinically significant obstructive pulmonary disease asthma control treatment time previous 3 month . Patients recent ( &lt; 2 year ) hematological/oncological disorder . Evidence clinically significant , active gastrointestinal , renal , hepatic , endocrine cardiovascular system disease . Patients current DSMlV diagnosis Major Depressive Disorder ( MDD ) current primary psychiatric diagnosis AD ( per DSMlV ) . Patients dementia complicate delirium ( DSM 290.30 290.11 ) ; depression delusion common AD , patient severe symptom pronounce warrant alternative , concurrent diagnosis , exclude . Patients know suspected history alcoholism drug abuse ( within past 5 year ) . Patients treat vitamin B12 deficiency stable dose medication least 3 month prior study screen visit normal serum B12 level screen . Patients treat hypothyroidism stable dose medication 3 month prior screen normal serum T4 TSH screen . Patients diabetes mellitus control diet , oral medication , insulin HbA1c &lt; 8.0 % random serum glucose value &lt; 170 mg/dl . Patients previously treat Aricept® ( donepezil Hydrochloride ) . Any condition would make patient caregiver , opinion investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Mild Moderate Alzheimer 's Disease</keyword>
	<keyword>Hispanic</keyword>
	<keyword>Latino</keyword>
	<keyword>Spanish-speaking</keyword>
</DOC>